Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.

Download Full-text

Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity

Prenatal Diagnosis ◽

10.1002/pd.594 ◽

2003 ◽

Vol 23 (4) ◽

pp. 331-335 ◽

Cited By ~ 43

Author(s):

Fran�oise Muller ◽

Sophie Dreux ◽

Henry Dupoizat ◽

Serge Uzan ◽

Marie-Fran�oise Dubin ◽

...

Keyword(s):

Down Syndrome ◽

Maternal Serum ◽

Second Trimester ◽

Maternal Serum Screening ◽

Serum Screening ◽

Twin Pregnancies

Download Full-text

Maternal Serum Invasive Trophoblast Antigen (Hyperglycosylated hCG) as a Screening Marker for Down Syndrome during the Second Trimester

Clinical Chemistry ◽

10.1373/clinchem.2004.038059 ◽

2004 ◽

Vol 50 (10) ◽

pp. 1804-1808 ◽

Cited By ~ 20

Author(s):

Glenn E Palomaki ◽

Louis M Neveux ◽

George J Knight ◽

James E Haddow ◽

Raj Pandian

Keyword(s):

United States ◽

Down Syndrome ◽

False Positive Rate ◽

The United States ◽

Maternal Serum ◽

Second Trimester ◽

Marker Panel ◽

Screening Performance ◽

Β Hcg ◽

Screening Marker

Abstract Background: Approximately two million pregnancies in the United States are screened for Down syndrome annually by use of second-trimester maternal serum markers. At present, a combination of four markers can identify 75% of affected pregnancies when 5% of screened women are classified as candidates for amniocentesis. Although not currently included in screening panels, invasive trophoblast antigen (ITA) is a promising screening marker in serum or urine in both the second and first trimesters. This study aims at better defining the screening performance of serum ITA in the second trimester. Methods: In an earlier study, serum samples from an unbiased sampling of 45 Down syndrome (cases) and 238 unaffected (control) pregnancies between 14 and 20 weeks of gestation were collected from various centers in the United States. Samples were aliquoted and stored at −20 °C for 8 years. We measured ITA in these samples and determined the screening performance both univariately and in combination with other screening markers. Results: The median ITA in Down syndrome pregnancies was >3.00 multiples of the median, higher than that found for human chorionic gonadotropin (hCG) or free β-hCG. At a 5% false-positive rate, ITA univariately detected 38% and 40% of Down syndrome pregnancies, respectively, when assigned by date of last menstrual period or ultrasound date. Modeling yielded rates of 45% and 48%. ITA correlated strongly with hCG and free β-hCG. When substituted for either of these in a multiple marker panel, ITA performed comparably. Conclusions: This study indicates that serum ITA is an effective marker for Down syndrome. It is highly correlated with both hCG and free β-hCG and could replace either of them in a multiple marker panel.

Download Full-text

Maternal serum placental growth factor and α -fetoprotein testing in first trimester screening for Down syndrome

Prenatal Diagnosis ◽

10.1002/pd.4087 ◽

2013 ◽

Vol 33 (5) ◽

pp. 457-461 ◽

Cited By ~ 19

Author(s):

Kim Donalson ◽

Steve Turner ◽

Lesley Morrison ◽

Päivi Liitti ◽

Christel Nilsson ◽

...

Keyword(s):

Down Syndrome ◽

Growth Factor ◽

First Trimester ◽

Maternal Serum ◽

Placental Growth Factor ◽

First Trimester Screening ◽

Trimester Screening

Download Full-text

Second-trimester maternal serum screening for fetal Down syndrome: As a screening test for hemoglobin Bart's disease: A prospective population-based study

Prenatal Diagnosis ◽

10.1002/pd.5316 ◽

2018 ◽

Vol 38 (9) ◽

pp. 700-705 ◽

Cited By ~ 1

Author(s):

Chanane Wanapirak ◽

Wirawit Piyamomgkol ◽

Supatra Sirichotiyakul ◽

Fuanglada Tongprasert ◽

Kasemsri Srisupundit ◽

...

Keyword(s):

Down Syndrome ◽

Screening Test ◽

Population Based ◽

Maternal Serum ◽

Second Trimester ◽

Maternal Serum Screening ◽

Population Based Study ◽

Serum Screening

Download Full-text